RIGL FY 2018 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$517M

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$45M+892.6% YoY

Gross Profit

$44M99.4% margin

Operating Income

-$73M-163.3% margin

Net Income

-$70M-158.3% margin

EPS (Diluted)

$-4.40

Cash Flow

Operating Cash Flow

-$59M

Free Cash Flow

-$60M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$139M

Total Liabilities

$29M

Stockholders' Equity

$110M

Cash & Equivalents

$76M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$45M	$4M	+892.6%
Gross Profit	$44M	-$42M	+205.8%
Operating Income	-$73M	-$80M	+8.7%
Net Income	-$70M	-$78M	+9.6%